Clover Biopharmaceuticals

Clover Biopharmaceuticals is a global commercial-stage biotechnology company focused on developing innovative vaccines and biologic therapeutics. The company utilizes its proprietary Trimer-Tag vaccine technology platform to create novel vaccines and biologic therapies. Clover's lead product is SCB-2019, a Covid-19 vaccine candidate based on a stabilized trimeric form of the SARS-CoV-2 spike protein. In clinical trials, SCB-2019 demonstrated 100% efficacy against severe Covid-19 and hospitalization. The vaccine also showed 84% efficacy in preventing household transmission of SARS-CoV-2. In December 2022, Clover's Covid-19 vaccine received emergency use authorization in China. The company launched the vaccine in China in February 2023 as part of the country's second booster dose campaign targeting older adults and high-risk groups.

Beyond Covid-19, Clover is developing other vaccine candidates, including SCB-1019, a bivalent RSV vaccine that entered Phase I clinical trials in December 2023. The company is also advancing SCB-219 million, a treatment for chemotherapy-induced thrombocytopenia that showed promising results in Phase I trials in December 2023. Clover has expanded its research and development capabilities, beginning construction on a new R&D center in Shanghai in January 2022. The 25,000 square meter facility is expected to include preclinical research labs, process development labs, and a GMP pilot manufacturing plant.